For anyone in Agoy looking to source CJC-1295, the key fact to understand is that this compound moves through online research channels. The core insight for Agoy researchers: sourcing CJC-1295 comes down completely to vendor quality evaluation, not geography — and the evaluation methodology is the same regardless of where you are. A legitimate CJC-1295 supplier's COA must contain HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all traceable to your specific batch. Use this guide to evaluate CJC-1295 vendors rigorously — the framework here are universal across all research contexts.
CJC-1295: What the Research Shows
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Agoy studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
How to Source CJC-1295 — Vendor Guide
Evaluating CJC-1295 vendors begins with the COA: locate the batch-specific certificate before placing an order, not after. Mass spectrometry in the COA verifies that the main HPLC peak is actually CJC-1295 and not another compound with similar chromatographic behaviour — HPLC purity alone does not confirm what the compound actually is. For Agoy researchers evaluating vendors with limited track records: a modest first purchase to test the product before placing larger orders is standard practice in the community. Store lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the amount needed for the near-term protocol and keep the remainder frozen.
Order CJC-1295 — ships to Agoy
COA-verified · International tracking · Research grade
All use of CJC-1295 in Agoy or anywhere constitutes research use — this compound is not approved for clinical human use, and all handling should comply with standard research safety practices. Temperature excursions — even temporary temperature deviation — can partially degrade CJC-1295 without any obvious sign; always maintain cold chain and work with cold-shipped material. Bacterial endotoxin contamination is the greatest safety hazard unique to this class of compound — verify endotoxin testing is included in the batch-specific COA before any injectable research application. Researchers using CJC-1295 alongside other research compounds should examine published studies for potential interaction data before proceeding with any multi-compound protocol.
Frequently Asked Questions
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
